d. Pro at position 217 is replaced by any naturally occurring amino acid other than Pro;
e. Arg at position 218 is replaced by any naturally occurring amino acid other than Arg;
f. Ala at position 219 is replaced by any naturally occurring amino acid other than Ala;
g. Gly at position 220 is replaced by any naturally occurring amino acid other than Gly;
h. Arg at position 221 is replaced by any naturally occurring amino acid other than Arg;
i. Ala at position 222 is replaced by any naturally occurring amino acid other than Ala.

3. (Amended) A FLINT analog as in Claim [1] 2 comprising an amino acid substitution in the region defined by amino acids 214 through 222 of SEQ ID NO:1, selected from the group consisting of:

a. Gly at position 214 is replaced by a positively charged amino acid that is not Gly;
b. Pro at position 215 is replaced by a positively charged amino acid that is not Pro;
c. Thr at position 216 is replaced by a positively charged amino acid that is not Thr;
d. Pro at position 217 is replaced by a positively charged amino acid that is not Pro;
e. Arg at position 218 is replaced by a positively charged amino acid that is not Arg;
f. Ala at position 219 is replaced by a positively charged amino acid that is not Ala;
g. Gly at position 220 is replaced by a positively charged amino acid that is not Gly;
h. Arg at position 221 is replaced by a positively charged amino acid that is not Arg; or

i. Ala at position 222 is replaced by a positively charged amino acid that is not Ala.

4. (Amended) A FLINT analog as in Claim [1] 2 comprising an amino acid substitution in the region defined by amino acids 214 - 222 of SEQ ID NO:1, selected from the group consisting of:

a. Gly at position 214 is replaced by a negatively charged amino acid that is not Gly;

b. Pro at position 215 is replaced by a negatively charged amino acid that is not Pro;

c. Thr at position 216 is replaced by a negatively charged amino acid that is not Thr;

d. Pro at position 217 is replaced by a negatively charged amino acid that is not Pro;

e. Arg at position 218 is replaced by a negatively charged amino acid that is not Arg;

f. Ala at position 219 is replaced by a negatively charged amino acid that is not Ala;

g. Gly at position 220 is replaced by a negatively charged amino acid that is not Gly;

h. Arg at position 221 is replaced by a negatively charged amino acid that is not Arg; or

i. Ala at position 222 is replaced by a negatively charged amino acid that is not Ala.

5. (Amended) A FLINT analog as in Claim [1] 2 comprising an amino acid substitution in the region defined by amino acids 214 - 222 of SEQ ID NO:1, selected from the group consisting of:

a. Gly at position 214 is replaced by a polar uncharged amino acid that is not Gly;

b. Pro at position 215 is replaced by a polar uncharged amino acid that is not Pro;
c. Thr at position 216 is replaced by a polar uncharged amino acid that is not Thr;
d. Pro at position 217 is replaced by a polar uncharged amino acid that is not Pro;
e. Arg at position 218 is replaced by a polar uncharged amino acid that is not Arg;
f. Ala at position 219 is replaced by a polar uncharged amino acid that is not Ala;
g. Gly at position 220 is replaced by a polar uncharged amino acid that is not Gly;
h. Arg at position 221 is replaced by a polar uncharged amino acid that is not Arg; or
i. Ala at position 222 is replaced by a polar uncharged amino acid that is not Ala.

6. (Amended) A FLINT analog as in Claim [1] 2 comprising an amino acid substitution in the region defined by amino acids 214 - 222 of SEQ ID NO:1, selected from the group consisting of:

a. Gly at position 214 is replaced by a nonpolar amino acid that is not Gly;
b. Pro at position 215 is replaced by a nonpolar amino acid that is not Pro;
c. Thr at position 216 is replaced by a nonpolar amino acid that is not Thr;
d. Pro at position 217 is replaced by a nonpolar amino acid that is not Pro;
e. Arg at position 218 is replaced by a nonpolar amino acid that is not Arg;
f. Ala at position 219 is replaced by a nonpolar amino acid that is not Ala;

g. Gly at position 220 is replaced by a nonpolar amino acid that is not Gly;

h. Arg at position 221 is replaced by a nonpolar amino acid that is not Arg; or

A1 Cancel

i. Ala at position 222 is replaced by a nonpolar amino acid that is not Ala.

7. (Amended) A FLINT analog [as in Claim 1] resistant to proteolysis at position 218 of SEQ ID NO:1 comprising an amino acid substitution in SEQ ID NO:1, selected from the group consisting of:

a. Arg at position 218 is replaced by Gln;

b. Arg at position 218 is replaced by Glu;

c. Thr at position 216 is replaced by Pro;

d. Arg at position 218 is replaced by Ala;

e. Arg at position 218 is replaced by Gly;

f. Arg at position 218 is replaced by Ser;

g. Arg at position 218 is replaced by Val

h. Arg at position 218 is replaced by Tyr;

i. Arg at position 218 is replaced by Asn; and

j. Pro at position 217 is replaced by Tyr.

A2

14. (Amended) A method to treat or prevent a disease or condition in a mammal comprising the administration of a therapeutically-effective amount of a protease resistant FLINT analog of Claim [1-13] 2.

A3

16. (Amended) A pharmaceutical formulation comprising as an active ingredient a protease resistant FLINT analog of Claim [1-13] 2 associated with one or more pharmaceutically acceptable carriers, excipients, or diluents thereof.